---
title: "Inflammatory Skin Conditions"
order: 2
category: "Dermatology"
---

# Inflammatory Skin Conditions

## Overview

Inflammatory skin conditions represent a diverse group of disorders characterized by immune-mediated inflammation of the skin. These conditions range from common chronic diseases like eczema and psoriasis to acute inflammatory conditions like contact dermatitis. Understanding the pathophysiology, clinical presentation, and management of these conditions is essential for effective patient care. This chapter focuses on three major inflammatory skin conditions: atopic dermatitis (eczema), psoriasis, and acne vulgaris.

### Classification
- **Chronic inflammatory**: Atopic dermatitis, psoriasis, rosacea
- **Acute inflammatory**: Contact dermatitis, drug eruptions
- **Sebaceous gland disorders**: Acne vulgaris, rosacea
- **Interface dermatitis**: Lichen planus, lupus erythematosus

### Epidemiology
- **Prevalence**: Affects 20-30% of the population at some point in life
- **Age distribution**: Some conditions (atopic dermatitis) peak in childhood; others (rosacea) in middle age
- **Impact**: Significant effect on quality of life, psychosocial functioning
- **Economic burden**: Direct and indirect costs in billions annually

## Atopic Dermatitis (Eczema)

### Definition and Classification
Atopic dermatitis is a chronic, relapsing inflammatory skin disease characterized by pruritus, eczematous lesions, and a typical age-specific distribution pattern. It is often the first manifestation of the atopic march, which may progress to asthma and allergic rhinitis.

#### Atopic March
- **Sequence**: Atopic dermatitis → food allergy → allergic rhinitis → asthma
- **Progression**: Not universal; approximately 50% of children with AD develop asthma
- **Mechanism**: Sensitization through damaged skin barrier
- **Prevention**: Early aggressive AD treatment may reduce progression

### Pathophysiology

#### Skin Barrier Dysfunction
- **Filaggrin mutations**: Loss-of-function mutations in 20-30% of European AD patients
- **Ceramide deficiency**: Reduced lipid content in stratum corneum
- **Increased TEWL**: Transepidermal water loss leading to xerosis
- **pH elevation**: Altered skin surface pH affects enzyme activity

#### Immune Dysregulation
- **Th2 dominance**: IL-4, IL-13, IL-31 drive acute inflammation
- **Th1 contribution**: Chronic lesions show Th1 activation (IFN-γ)
- **Th22 activation**: IL-22 contributes to epidermal hyperplasia
- **IgE elevation**: Total and allergen-specific IgE often elevated

#### Microbial Dysbiosis
- **S. aureus colonization**: Present in 70-90% of AD skin
- **Enterotoxins**: Superantigens exacerbate inflammation
- **Bacterial diversity**: Reduced diversity during flares
- **Malassezia**: May contribute to head/neck AD

### Clinical Presentation

#### Infantile Pattern (2 months - 2 years)
- **Distribution**: Face (cheeks), scalp, extensor surfaces
- **Morphology**: Acute eczema with erythema, vesiculation, weeping, crusting
- **Sparing**: Diaper area typically spared
- **Pruritus**: Scratching, rubbing against surfaces

#### Childhood Pattern (2-12 years)
- **Distribution**: Flexural areas (antecubital, popliteal fossae), neck, wrists, ankles
- **Morphology**: Subacute to chronic eczema with lichenification
- **Complications**: Secondary infection, sleep disturbance
- **Hand involvement**: Hand dermatitis may develop

#### Adult Pattern (>12 years)
- **Distribution**: Flexures, hands, eyelids, face, neck
- **Morphology**: Lichenified plaques, excoriations, prurigo nodules
- **Variants**: Hand eczema, nipple eczema, chronic lip licking
- **Persistence**: Approximately 50% have persistence from childhood

#### Associated Features
- **Dennie-Morgan folds**: Infraorbital folds
- **Keratosis pilaris**: Follicular hyperkeratosis on arms and thighs
- **Ichthyosis vulgaris**: Dry, scaly skin with palmar hyperlinearity
- **Pityriasis alba**: Hypopigmented patches on face and arms

### Diagnosis

#### Clinical Criteria (Hanifin and Rajka)
**Major criteria (3 of 4 required):**
- Pruritus
- Typical morphology and distribution
- Chronic or chronically relapsing course
- Personal or family history of atopy

**Minor criteria (3 or more):**
- Xerosis
- Ichthyosis, palmar hyperlinearity, keratosis pilaris
- IgE reactivity
- Early age of onset
- Recurrent infections
- Nonspecific hand/foot dermatitis
- Nipple eczema
- Anterior subcapsular cataracts
- Dennie-Morgan infraorbital fold
- Facial pallor or erythema

#### Laboratory Testing
- **Not routinely required**: Diagnosis is clinical
- **Total IgE**: Often elevated but not diagnostic
- **Allergen-specific IgE**: May guide allergen avoidance
- **Patch testing**: For suspected contact dermatitis
- **Skin biopsy**: Rarely needed, shows spongiosis

### Treatment

#### Skin Care and Prevention
- **Emollients**: Frequent application (2-4 times daily)
- **Bathing**: Brief lukewarm baths, immediate moisturization
- **Soap substitutes**: Gentle, fragrance-free cleansers
- **Trigger avoidance**: Irritants, allergens, extreme temperatures
- **Clothing**: Soft fabrics, avoid wool and synthetic materials

#### Topical Therapy
**Corticosteroids:**
- **Potency selection**: Based on severity and location
- **Application**: Once to twice daily to affected areas
- **Duration**: Short-term flares, not continuous long-term use
- **Face/flexures**: Low to mid-potency only
- **Side effects**: Atrophy, striae, perioral dermatitis

**Calcineurin Inhibitors:**
- **Agents**: Tacrolimus 0.03% and 0.1%, pimecrolimus 1%
- **Mechanism**: Inhibit T-cell activation
- **Indications**: Steroid-sensitive areas, long-term control
- **Side effects**: Burning (first week), theoretical cancer risk (black box warning)

**PDE4 Inhibitor:**
- **Crisaborole 2%**: Anti-inflammatory ointment
- **Indication**: Mild to moderate AD, age ≥3 months
- **Mechanism**: Phosphodiesterase-4 inhibition
- **Application**: Twice daily

#### Systemic Therapy
**Antihistamines:**
- **Indication**: Pruritus, sleep disturbance
- **Agents**: Sedating (hydroxyzine, diphenhydramine) at bedtime
- **Limitation**: Limited efficacy for AD pruritus

**Systemic Immunosuppressants:**
- **Cyclosporine**: 3-5 mg/kg/day, rapid onset, short-term use
- **Methotrexate**: 7.5-25 mg weekly, slower onset, better for long-term
- **Azathioprine**: 1-3 mg/kg/day, slower onset
- **Mycophenolate mofetil**: 2-3 g/day, slower onset
- **Monitoring**: CBC, liver function, renal function, blood pressure

**Biologics:**
- **Dupilumab**: IL-4/IL-13 inhibitor, subcutaneous injection every 2 weeks
- **Efficacy**: 50-70% achieve significant improvement
- **Side effects**: Conjunctivitis, injection site reactions
- **Advantages**: Well-tolerated, long-term safety data

**JAK Inhibitors:**
- **Upadacitinib, baricitinib, abrocitinib**: Oral JAK inhibitors
- **Efficacy**: Rapid onset, high efficacy
- **Monitoring**: Infections, laboratory parameters
- **Warnings**: Black box warnings for infections, malignancy, thrombosis

#### Phototherapy
- **Narrowband UVB**: First-line phototherapy
- **Frequency**: 2-3 times weekly
- **Duration**: 2-3 months for optimal response
- **Limitations**: Requires access to phototherapy unit

#### Treatment of Complications
**Secondary infection:**
- **S. aureus**: Topical mupirocin or oral antibiotics (cephalexin, dicloxacillin)
- **Bleach baths**: Dilute sodium hypochlorite (1/4 cup in full tub) 2x/week
- **Eczema herpeticum**: IV acyclovir if severe

### Prognosis and Natural History
- **Resolution**: 50-70% of children show improvement by adolescence
- **Predictors of persistence**: Early onset, severe disease, family history, filaggrin mutations
- **Adult onset**: May have more persistent course
- **Quality of life**: Significant impact on sleep, social functioning, work/school

## Psoriasis

### Definition and Classification
Psoriasis is a chronic, immune-mediated inflammatory disease characterized by well-demarcated, erythematous plaques with silvery scale. It has significant genetic predisposition and can be associated with psoriatic arthritis and metabolic syndrome.

#### Clinical Subtypes
- **Plaque psoriasis (psoriasis vulgaris)**: 80-90% of cases
- **Guttate psoriasis**: Acute, droplet-like lesions, often post-streptococcal
- **Inverse psoriasis**: Smooth plaques in intertriginous areas
- **Pustular psoriasis**: Sterile pustules (localized or generalized)
- **Erythrodermic psoriasis**: >90% body surface involvement

### Pathophysiology

#### Genetic Factors
- **Heritability**: 60-90% based on twin studies
- **HLA associations**: HLA-Cw6 (type 1 early-onset psoriasis)
- **PSORS loci**: Multiple susceptibility loci identified
- **Polygenic inheritance**: Multiple genes with environmental triggers

#### Immunologic Mechanisms
- **IL-23/Th17 axis**: Central pathway in psoriasis pathogenesis
- **Cytokine cascade**: IL-23 → Th17 cells → IL-17A, IL-17F, IL-22
- **Keratinocyte proliferation**: IL-17 and IL-22 stimulate hyperproliferation
- **TNF-α**: Amplifies inflammatory response

#### Cellular Pathology
- **Epidermal changes**: Acanthosis, parakeratosis, loss of granular layer
- **Dermal infiltrate**: T cells, dendritic cells, neutrophils
- **Vascular changes**: Elongated dermal papillae, dilated capillaries
- **Turnover time**: Reduced from 28 days to 3-5 days

### Clinical Presentation

#### Plaque Psoriasis
- **Appearance**: Well-demarcated, erythematous plaques with silvery-white scale
- **Distribution**: Elbows, knees, scalp, lumbosacral area, gluteal cleft
- **Size**: Variable, from small plaques to large confluent areas
- **Symptoms**: Usually asymptomatic, occasional pruritus

#### Scalp Psoriasis
- **Prevalence**: 50-80% of psoriasis patients
- **Appearance**: Thick, adherent scale on erythematous base
- **Extent**: May extend beyond hairline
- **Differential**: Seborrheic dermatitis (less well-demarcated)

#### Nail Psoriasis
- **Prevalence**: 40-50% of psoriasis patients, 80-90% with psoriatic arthritis
- **Nail pitting**: Small depressions in nail plate
- **Oil spots**: Yellow-brown discoloration under nail plate
- **Onycholysis**: Separation of nail from nail bed
- **Subungual hyperkeratosis**: Thickening under nail

#### Guttate Psoriasis
- **Presentation**: Acute eruption of small (2-10mm) droplet-like papules
- **Trigger**: Often 2-3 weeks after streptococcal pharyngitis
- **Distribution**: Trunk and proximal extremities
- **Prognosis**: May resolve or progress to plaque psoriasis

#### Inverse Psoriasis
- **Location**: Axillae, groin, inframammary, intergluteal
- **Appearance**: Smooth, well-demarcated, shiny erythematous plaques
- **Scale**: Minimal due to moisture
- **Differential**: Candidiasis, dermatophyte infection

#### Pustular Psoriasis
- **Generalized (von Zumbusch)**: Acute, widespread sterile pustules, fever, systemic illness
- **Localized (palmoplantar pustulosis)**: Chronic pustules on palms and soles
- **Triggers**: Medications (steroids, lithium), infection, pregnancy
- **Urgency**: Generalized form is medical emergency

#### Erythrodermic Psoriasis
- **Definition**: Erythema and scale involving >90% body surface
- **Triggers**: Abrupt steroid withdrawal, severe sunburn, infection
- **Complications**: Temperature dysregulation, high-output cardiac failure, infection
- **Management**: Hospitalization often required

### Associated Conditions

#### Psoriatic Arthritis
- **Prevalence**: 10-30% of psoriasis patients
- **Patterns**: Distal interphalangeal, asymmetric oligoarthritis, symmetric polyarthritis, spondylitis, arthritis mutilans
- **Timing**: Can precede, coincide with, or follow skin disease
- **Screening**: Nail involvement increases risk

#### Metabolic Syndrome
- **Components**: Obesity, hypertension, dyslipidemia, insulin resistance
- **Prevalence**: 2-3 times higher in psoriasis patients
- **Bidirectional**: Inflammation contributes to metabolic disease
- **Screening**: Annual assessment recommended

#### Cardiovascular Disease
- **Risk**: Independent cardiovascular risk factor
- **Mechanism**: Systemic inflammation, endothelial dysfunction
- **Severity correlation**: Worse with severe psoriasis
- **Management**: Aggressive CV risk factor modification

#### Psychological Impact
- **Depression**: 2-3 times higher prevalence
- **Anxiety**: Common comorbidity
- **Quality of life**: Significant impairment comparable to other major diseases
- **Stigma**: Social isolation, impact on relationships

### Diagnosis

#### Clinical Diagnosis
- **Based on**: Morphology, distribution, course
- **Auspitz sign**: Pinpoint bleeding when scale removed
- **Koebner phenomenon**: New lesions at sites of trauma
- **Biopsy**: Rarely needed, shows characteristic histology

#### Disease Severity Assessment
**Psoriasis Area and Severity Index (PASI):**
- **Components**: Area, erythema, induration, desquamation
- **Range**: 0-72
- **Mild**: PASI <10, BSA <10%
- **Moderate to severe**: PASI >10 or BSA >10%

**Body Surface Area (BSA):**
- **Measurement**: Patient's palm = 1% BSA
- **Mild**: <3% BSA
- **Moderate**: 3-10% BSA
- **Severe**: >10% BSA

**Dermatology Life Quality Index (DLQI):**
- **Questions**: 10 questions on impact
- **Range**: 0-30
- **Interpretation**: >10 indicates severe impact

### Treatment

#### Topical Therapy (Mild Disease)
**Corticosteroids:**
- **First-line**: Various potencies based on location
- **Body**: Mid- to high-potency
- **Face/flexures**: Low-potency
- **Scalp**: Solutions, foams for penetration
- **Limitation**: Tachyphylaxis, rebound on discontinuation

**Vitamin D Analogues:**
- **Calcipotriene**: Often combined with corticosteroid
- **Mechanism**: Inhibits keratinocyte proliferation
- **Application**: Twice daily, up to 100g/week
- **Side effects**: Irritation, hypercalcemia (if excessive use)

**Topical Retinoids:**
- **Tazarotene**: Normalizes keratinocyte differentiation
- **Efficacy**: Moderate, often combined with corticosteroid
- **Side effects**: Irritation, teratogenic

**Calcineurin Inhibitors:**
- **Use**: Off-label for facial and intertriginous psoriasis
- **Advantage**: No atrophy risk

**Coal Tar:**
- **Traditional therapy**: Anti-inflammatory, antiproliferative
- **Formulations**: Shampoos, ointments, bath preparations
- **Limitations**: Odor, staining, time-consuming

#### Phototherapy (Moderate Disease)
**Narrowband UVB:**
- **Frequency**: 3 times weekly
- **Duration**: 2-3 months to achieve clearance
- **Maintenance**: Possible with reduced frequency
- **Side effects**: Sunburn, photoaging, skin cancer risk

**PUVA (Psoralen + UVA):**
- **Indication**: Recalcitrant disease
- **Method**: Oral or topical psoralen, then UVA exposure
- **Efficacy**: Higher than UVB but more side effects
- **Risks**: Nausea, photoaging, squamous cell carcinoma

**Excimer Laser:**
- **Indication**: Localized plaques
- **Wavelength**: 308nm targeted UVB
- **Advantage**: Spares uninvolved skin
- **Frequency**: 2-3 times weekly

#### Systemic Therapy (Moderate to Severe Disease)

**Conventional Systemic Agents:**

*Methotrexate:*
- **Dosing**: 7.5-25 mg weekly, oral or subcutaneous
- **Folic acid**: 1 mg daily to reduce side effects
- **Monitoring**: CBC, liver function, creatinine at baseline and every 3 months
- **Contraindications**: Pregnancy, liver disease, significant alcohol use
- **Advantages**: Treats both skin and joint disease, low cost

*Cyclosporine:*
- **Dosing**: 2.5-5 mg/kg/day divided twice daily
- **Use**: Short-term (up to 1 year) or intermittent
- **Monitoring**: Blood pressure, creatinine, potassium
- **Side effects**: Nephrotoxicity, hypertension, immunosuppression
- **Advantages**: Rapid onset (2-4 weeks)

*Acitretin:*
- **Dosing**: 10-50 mg daily
- **Indication**: Pustular and erythrodermic psoriasis
- **Side effects**: Teratogenicity (avoid pregnancy for 3 years after), mucocutaneous dryness, lipid elevation
- **Advantage**: Can combine with phototherapy
- **Monitoring**: Lipids, liver function

**Biologic Therapies:**

*TNF Inhibitors:*
- **Agents**: Etanercept, adalimumab, infliximab, certolizumab
- **Efficacy**: PASI 75 in 50-80% at 12 weeks
- **Administration**: Subcutaneous or IV
- **Screening**: Tuberculosis, hepatitis B
- **Side effects**: Injection reactions, infections, malignancy risk

*IL-12/23 Inhibitor:*
- **Ustekinumab**: Targets p40 subunit shared by IL-12 and IL-23
- **Dosing**: Based on weight, every 12 weeks after loading
- **Efficacy**: PASI 75 in 65-75% at 12 weeks
- **Side effects**: Infections, possible malignancy risk

*IL-23 Inhibitors:*
- **Agents**: Guselkumab, tildrakizumab, risankizumab
- **Mechanism**: Block p19 subunit of IL-23
- **Efficacy**: PASI 90 in 70-80% at 16 weeks
- **Dosing**: Every 8-12 weeks after loading
- **Advantages**: High efficacy, favorable safety profile, convenient dosing

*IL-17 Inhibitors:*
- **Agents**: Secukinumab, ixekizumab, brodalumab
- **Mechanism**: Block IL-17A (and IL-17RA for brodalumab)
- **Efficacy**: PASI 90 in 60-80% at 12 weeks
- **Side effects**: Candidiasis (especially oral), IBD exacerbation
- **Advantages**: Rapid onset, high efficacy

**Oral Small Molecules:**

*Apremilast:*
- **Mechanism**: PDE4 inhibitor
- **Dosing**: 30 mg twice daily (after titration)
- **Efficacy**: PASI 75 in 30-35% at 16 weeks
- **Advantages**: Oral, no laboratory monitoring required
- **Side effects**: Diarrhea, nausea, weight loss, depression

### Special Considerations

#### Pediatric Psoriasis
- **Presentation**: Often guttate, napkin psoriasis in infants
- **Treatment**: Topicals first-line, phototherapy and systemics if needed
- **Biologics**: Etanercept approved ≥4 years, others have pediatric approvals
- **Psychosocial**: Significant impact on quality of life

#### Pregnancy
- **Course**: May improve, worsen, or remain stable
- **Treatments**: Topical corticosteroids, UVB phototherapy considered safe
- **Contraindicated**: Methotrexate, acitretin, most biologics
- **Certolizumab**: Minimal placental transfer, option if needed

### Prognosis
- **Chronic course**: Lifelong disease with periods of remission and flare
- **Variable severity**: May fluctuate over time
- **Treatment response**: Most patients achieve significant improvement with appropriate therapy
- **Comorbidity impact**: Requires holistic management approach

## Acne Vulgaris

### Definition and Classification
Acne vulgaris is a chronic inflammatory disease of the pilosebaceous unit characterized by comedones, papules, pustules, and nodules. It primarily affects adolescents but can persist into or begin in adulthood.

#### Classification by Severity
- **Mild**: Comedonal acne, few inflammatory lesions
- **Moderate**: Inflammatory papules and pustules
- **Severe**: Nodules, cysts, scarring risk
- **Very severe**: Nodulocystic or conglobate acne

### Pathophysiology

#### Four Key Factors
**Increased Sebum Production:**
- **Trigger**: Androgens stimulate sebaceous gland activity
- **Puberty**: Hormonal changes increase sebum
- **Composition**: Altered lipid composition in acne patients
- **Distribution**: Acne affects sebum-rich areas

**Follicular Hyperkeratinization:**
- **Mechanism**: Abnormal desquamation of follicular epithelium
- **Result**: Microcomedone formation (earliest lesion)
- **Keratinocyte proliferation**: Increased and altered differentiation
- **Retention**: Sebum and keratin accumulation

**C. acnes Proliferation:**
- **Organism**: Cutibacterium acnes (formerly Propionibacterium acnes)
- **Environment**: Anaerobe thrives in lipid-rich, occluded follicle
- **Inflammatory trigger**: Releases enzymes, activates immune response
- **Biofilm formation**: Contributes to antibiotic resistance

**Inflammation:**
- **Innate immunity**: TLR activation, cytokine release
- **Neutrophil recruitment**: Inflammatory papules and pustules
- **Rupture**: Follicular wall rupture causes nodule/cyst formation
- **Scarring**: Result of severe inflammation

#### Hormonal Influences
- **Androgens**: Stimulate sebaceous glands
- **Estrogens**: Generally protective
- **PCOS**: Hyperandrogenism causes acne in women
- **Adrenal androgens**: DHEA-S contribution

### Clinical Presentation

#### Lesion Types
**Non-inflammatory:**
- **Open comedone (blackhead)**: Dilated follicle with dark plug
- **Closed comedone (whitehead)**: Closed follicle with white papule
- **Location**: Face, chest, back

**Inflammatory:**
- **Papules**: Small (<5mm) erythematous, tender bumps
- **Pustules**: White or yellow pus-filled lesions
- **Nodules**: Large (>5mm), deep, painful
- **Cysts**: Fluctuant, pus-filled nodules

#### Distribution
- **Face**: Most common, especially T-zone (forehead, nose, chin)
- **Chest**: Upper chest and shoulders
- **Back**: Upper back and shoulders
- **Predictive**: Facial acne predicts truncal involvement

#### Variants and Subtypes

**Acne Conglobata:**
- **Severity**: Most severe form
- **Features**: Multiple nodules, cysts, abscesses, interconnecting sinuses
- **Scarring**: Extensive and disfiguring
- **Demographics**: Young adult males

**Acne Fulminans:**
- **Onset**: Sudden, severe nodulocystic acne
- **Systemic**: Fever, arthralgias, malaise
- **Laboratory**: Elevated ESR, leukocytosis
- **Treatment**: Corticosteroids, isotretinoin

**Hormonal Acne (Women):**
- **Pattern**: Lower face, jawline, neck
- **Timing**: Premenstrual flares
- **Age**: Persistent beyond adolescence
- **Associated**: Hirsutism, irregular menses (consider PCOS)

**Acne Mechanica:**
- **Cause**: Friction, pressure, occlusion
- **Examples**: Helmets, headbands, shoulder pads, backpacks
- **Distribution**: Corresponds to source of mechanical irritation

**Pomade Acne:**
- **Cause**: Occlusive hair products
- **Distribution**: Forehead, temples, hairline
- **Population**: More common in individuals using hair pomades

### Diagnosis

#### Clinical Assessment
- **History**: Age of onset, duration, previous treatments, family history
- **Medications**: Corticosteroids, lithium, anticonvulsants, hormones
- **Cosmetics**: Use of comedogenic products
- **Occupation**: Exposure to oils, grease
- **Women**: Menstrual history, signs of hyperandrogenism

#### Physical Examination
- **Severity grading**: Count and classify lesions
- **Distribution**: Facial, truncal
- **Scarring**: Type and extent
- **Post-inflammatory changes**: Erythema, hyperpigmentation

#### Laboratory Evaluation
- **Usually not needed**: Diagnosis is clinical
- **Consider in women**: Total testosterone, free testosterone, DHEA-S, LH/FSH ratio
- **Indications**: Severe acne, hirsutism, irregular menses, treatment resistance
- **PCOS screening**: If clinical suspicion

### Treatment

#### General Principles
- **Combination therapy**: More effective than monotherapy
- **Maintenance**: Continue treatment after clearance to prevent recurrence
- **Patience**: Most treatments require 6-8 weeks to show benefit
- **Side effects**: Inform patients about dryness, irritation

#### Topical Therapy

**Retinoids:**
- **Agents**: Tretinoin, adapalene, tazarotene, trifarotene
- **Mechanism**: Normalize follicular keratinization, anti-inflammatory
- **Indication**: Comedonal and inflammatory acne, first-line
- **Application**: Evening, start every other night, gradually increase
- **Side effects**: Dryness, erythema, photosensitivity, teratogenic

**Benzoyl Peroxide:**
- **Mechanism**: Antibacterial, keratolytic, anti-inflammatory
- **Concentrations**: 2.5-10% (lower as effective with less irritation)
- **Formulations**: Wash, gel, cream
- **Combination**: Often combined with retinoid or antibiotic
- **Side effects**: Dryness, bleaching of fabrics
- **Advantage**: No bacterial resistance

**Topical Antibiotics:**
- **Agents**: Clindamycin, erythromycin
- **Mechanism**: Reduce C. acnes, anti-inflammatory
- **Use**: Always combine with benzoyl peroxide to prevent resistance
- **Duration**: Limit to 3 months if possible
- **Formulations**: Lotion, gel, pledgets

**Azelaic Acid:**
- **Mechanism**: Antibacterial, anti-inflammatory, depigmenting
- **Concentrations**: 15-20%
- **Advantages**: Safe in pregnancy, treats post-inflammatory hyperpigmentation
- **Side effects**: Mild stinging, lightening

**Salicylic Acid:**
- **Mechanism**: Keratolytic, anti-inflammatory
- **Concentrations**: 0.5-2%
- **Use**: Over-the-counter, mild comedonal acne
- **Formulations**: Cleansers, pads, spot treatments

**Topical Dapsone:**
- **Concentration**: 5% gel
- **Mechanism**: Anti-inflammatory
- **Indication**: Inflammatory acne
- **Frequency**: Twice daily
- **Advantage**: Well-tolerated

#### Oral Therapy

**Antibiotics:**
- **Agents**: Doxycycline, minocycline, sarecycline, azithromycin
- **Mechanism**: Reduce C. acnes, anti-inflammatory
- **Duration**: 3-6 months, then taper
- **Always combine**: With topical retinoid and benzoyl peroxide
- **Side effects**: GI upset, photosensitivity (doxycycline), vertigo (minocycline)
- **Resistance**: Growing concern

**Hormonal Therapy (Women):**
*Combined Oral Contraceptives:*
- **FDA-approved**: Ortho Tri-Cyclen, Estrostep, Yaz, Beyaz
- **Mechanism**: Suppress ovarian androgen production, increase SHBG
- **Candidates**: Women with acne who desire contraception
- **Onset**: 3-6 months for acne benefit
- **Side effects**: Nausea, weight gain, mood changes, VTE risk

*Spironolactone:*
- **Dosing**: 50-200 mg daily
- **Mechanism**: Androgen receptor antagonist, reduces sebum
- **Indication**: Hormonal acne in women
- **Monitoring**: Potassium, blood pressure
- **Side effects**: Menstrual irregularities, breast tenderness, hyperkalemia
- **Contraindication**: Pregnancy (teratogenic)

**Isotretinoin:**
- **Indication**: Severe nodulocystic acne, moderate acne resistant to treatment
- **Mechanism**: Reduces sebum production, normalizes keratinization, anti-inflammatory
- **Dosing**: 0.5-1 mg/kg/day, cumulative dose 120-150 mg/kg
- **Duration**: 4-6 months typically
- **Efficacy**: >90% achieve long-term remission

*Monitoring Requirements:*
- **Pregnancy prevention**: iPLEDGE program in US, two forms of contraception
- **Laboratory**: Pregnancy test monthly, lipids and LFTs at baseline and during treatment
- **Consent**: Informed consent required

*Side Effects:*
- **Mucocutaneous**: Dry lips, eyes, skin (universal)
- **Musculoskeletal**: Arthralgias, myalgias
- **Metabolic**: Elevated triglycerides, cholesterol, LFTs
- **Psychiatric**: Controversial, may worsen depression (black box warning)
- **Teratogenicity**: Severe birth defects if taken during pregnancy

*Contraindications:*
- **Absolute**: Pregnancy, breastfeeding
- **Relative**: Inflammatory bowel disease, severe hypertriglyceridemia, liver disease

#### Procedural Treatments

**Comedone Extraction:**
- **Technique**: Manual removal with comedone extractor
- **Indication**: Stubborn closed and open comedones
- **Benefit**: Immediate improvement in appearance

**Intralesional Corticosteroid:**
- **Agent**: Triamcinolone acetonide 2.5-5 mg/mL
- **Indication**: Large, painful nodules
- **Effect**: Rapid reduction in size and inflammation (48-72 hours)
- **Risk**: Atrophy if concentration too high

**Chemical Peels:**
- **Agents**: Salicylic acid, glycolic acid
- **Mechanism**: Exfoliation, unclog pores
- **Frequency**: Every 2-4 weeks
- **Combination**: With topical regimen

**Laser and Light Therapies:**
- **Blue light**: Targets C. acnes porphyrins
- **Red light**: Anti-inflammatory
- **PDT**: Photodynamic therapy with aminolevulinic acid
- **Evidence**: Variable, adjunctive therapy

### Acne Scarring

#### Types
- **Ice pick**: Deep, narrow, pitted scars
- **Rolling**: Broad depressions with sloping edges
- **Boxcar**: Broad depressions with sharp edges
- **Hypertrophic**: Raised, thickened scars
- **Post-inflammatory hyperpigmentation**: Flat brown marks

#### Treatment
**Topical:**
- **Retinoids**: Improve texture, prevent new scarring
- **Azelaic acid, hydroquinone**: Post-inflammatory hyperpigmentation
- **Silicone gel**: Hypertrophic scars

**Procedural:**
- **Chemical peels**: Superficial to medium depth
- **Microneedling**: Stimulate collagen production
- **Laser resurfacing**: Ablative or non-ablative
- **Subcision**: Release tethered rolling scars
- **Fillers**: Temporary correction of atrophic scars
- **Punch techniques**: Excision or elevation

### Special Considerations

#### Neonatal and Infantile Acne
- **Neonatal**: First 6 weeks, maternal androgens
- **Infantile**: 3-16 months, transient androgen surge
- **Treatment**: Usually resolves spontaneously, mild cases may treat with topicals

#### Adult Acne
- **Definition**: Acne persisting beyond age 25 or new onset in adulthood
- **More common**: Women (hormonal factors)
- **Pattern**: Lower face, jawline
- **Evaluation**: Consider hormonal evaluation in women
- **Treatment**: Similar to adolescent acne, spironolactone useful in women

#### Acne in Pregnancy
- **Course**: Variable, may improve or worsen
- **Safe treatments**: Benzoyl peroxide, azelaic acid, topical erythromycin
- **Avoid**: Retinoids (oral and topical), doxycycline, hormonal therapy
- **Consider**: Natural improvement postpartum

#### Acne in Skin of Color
- **Post-inflammatory hyperpigmentation**: More common and severe
- **Treatment modifications**: Gentler approach to minimize irritation
- **Combination therapy**: Treat acne and pigmentation simultaneously
- **Agents**: Azelaic acid, retinoids, hydroquinone

### Prognosis
- **Most cases**: Resolve by mid-20s
- **Adult persistence**: 10-20% continue beyond age 25
- **Scarring**: Can be minimized with early aggressive treatment
- **Psychological impact**: Significant, can lead to depression and anxiety
- **Treatment success**: Most patients achieve good control with appropriate therapy

## Key Points

- Atopic dermatitis is characterized by pruritus, eczematous lesions, and age-specific distribution patterns with significant impact on quality of life
- Barrier dysfunction, immune dysregulation, and microbial dysbiosis contribute to atopic dermatitis pathophysiology
- Psoriasis is an immune-mediated disease driven by the IL-23/Th17 axis with multiple clinical subtypes and important comorbidities
- Biologic therapies targeting IL-23 and IL-17 have revolutionized moderate to severe psoriasis treatment
- Acne vulgaris results from increased sebum production, follicular hyperkeratinization, C. acnes proliferation, and inflammation
- Combination therapy is more effective than monotherapy for acne, with retinoids as first-line for most patients
- Isotretinoin is highly effective for severe acne but requires careful monitoring and pregnancy prevention
- Early aggressive treatment of inflammatory skin conditions can prevent scarring and improve long-term outcomes
- Patient education about chronic nature, realistic expectations, and adherence is crucial for success
- Multidisciplinary approach may be needed for severe cases and associated comorbidities

## References

1. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1.
2. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis. J Am Acad Dermatol. 2014;71(1):116-132.
3. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945-1960.
4. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072.
5. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.
